CA2117118C - Device for the direct measurement of low density lipoprotein cholesterol - Google Patents

Device for the direct measurement of low density lipoprotein cholesterol Download PDF

Info

Publication number
CA2117118C
CA2117118C CA002117118A CA2117118A CA2117118C CA 2117118 C CA2117118 C CA 2117118C CA 002117118 A CA002117118 A CA 002117118A CA 2117118 A CA2117118 A CA 2117118A CA 2117118 C CA2117118 C CA 2117118C
Authority
CA
Canada
Prior art keywords
density lipoprotein
low density
blood sample
layer
silica
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002117118A
Other languages
French (fr)
Other versions
CA2117118A1 (en
Inventor
Mary Margaret Foltz
Chen-Jung Hsu
Robert C. Payne
James A. Profitt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of CA2117118A1 publication Critical patent/CA2117118A1/en
Application granted granted Critical
Publication of CA2117118C publication Critical patent/CA2117118C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361Ion-exchange
    • B01D15/362Cation-exchange
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/02Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
    • B01J20/10Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
    • B01J20/103Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate comprising silica
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28002Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their physical properties
    • B01J20/28004Sorbent size or size distribution, e.g. particle size
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28054Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
    • B01J20/28078Pore diameter
    • B01J20/28083Pore diameter being in the range 2-50 nm, i.e. mesopores
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G01N33/525Multi-layer analytical elements
    • G01N33/526Multi-layer analytical elements the element being adapted for a specific analyte
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/044Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25125Digestion or removing interfering materials
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]

Abstract

Disclosed is a dry phase device for separating high density lipoprotein from a blood (serum or plasma) sample. The device comprises a fluid permeable material having dispersed therein finely divided, porous silica or silicate particles as selective absorbent for HDL.
By combining the device with a second layer designed to remove VLDL/chylomicrons from the blood, and a third layer containing means for quantitative cholesterol detection, there is provided a test device for the direct determination of LDL cholesterol.

Description

-...
DEVICE FOR THE DIRECT MEASUREMENT OF
LOW DENSITY LIPOPROTEIN CHOLESTEROL
Backctround ~f the Invention This invention relates to the field of clinical assay techniques and involves the measurement of low density lipoprotein cholesterol.
Lipoproteins are complex particles comprising proteins and lipids which are found in the circulatory system. One of their functions is to carry water insoluble substances, such as cholesterol and choles-terol esters, for eventual cellular utilization. While all cells require cholesterol for growth, the excess accumulation of cholesterol by cells can lead to certain diseases including ath0rosclerosis.
Therr are a variety of classes of lipoproteins in serum which can be classified by their density. These classes include very love density lipoproteins (vLDL),, lora density lipoproteins (LDL) and high density lipopro-teins {HDL): All of these lipopro-tins contain ~p varying amounts of cholesterol. A total serum choles°
terol determination is a GOmplex sum of the amount that each lipaprotei.n contributes to the total lipoprotein population of the serum.
MSE #1840 :~ ~.~~1~~
While it is known that the amount of total serum cholesterol can be correlated with the incidence of atherosclerosis, evidence from studies of recent years has shown that specific lipoprotein types are more closely associated with the progression of heart disease, including atherosclerosis, than others. More recent studies have implicated LDL as the class of lipoproteins responsible for. the accumulation of cholesterol in the cells whereas HDL has been shown to ZO be active in the removal of excess cholesterol from cells. Accordingly, various systems have been proposed for the measurement of cholesterol bearing lipoproteins in general and LDL in particular.
Amorphous silica, i.e. that form of Si02 which lacks a crystal structure, has been used as an adsorbent since at least as early as World War I when it was considered for use as an absorbent in gas masks.
Amorphous silica is broadly divided into three catego-ries: vitreous silica or glass made by fusing quart ;
silica M made by irradiating e9.ther amorphous or crystalline silica with high speed neutrons and micro-porous silica. 'Ihe microparticulate silicas include pyrogenic silicas and silicas precipitated from aqueous solution. P~yrogenic sili~as are formed at high tempera-tore by condensation of Si02 from the vapor phase, or at lower temperature by chemical reaction in the vapor phase followed by condensation.
Silica formed in aqueous solution can occur as sols, gels or particle. A gel has a three-dimensional, Continuous structure, whereas a sol is a stable dis-pension of fine particles.
MSE #1840 ~~' ~~~~.~
Silica gels axe classified into three types.
Regular density gel is made by gelling in an acid medium, which gives very small particles with high surface area (750-800 m2/g). The average pore diameter is 22-26 ~,, and the pore volume is 0.37-0.40 mL/g.
Regular density gel contains about 6 wt~ water as surface hydroxyl groups, which imparts a high propensity for adsorption of water and other polar molecules.
Regular density gel exhibits a high selectivity for Polar molecules and possesses a large percentage of small pores. Intermediate density silica has a lower surface area (300-350 mg2/g) but larger pore volume (0.5-1.1 mL/g). The average pore diameter is 120-180 A
in diameter and the particles are larger than'those of regular density gel. Because of the large pore size, intermediate density gel has a large capacity for water absorption at high humidifies. Low density silica gel has a lower surface area (<200 m2/g), larger pore diameter (>180 ~) and a larger pore volume (>1.5 mL/g) than the other types. It is usually prepared as a very fine powder of extremely low density. When silica is used as an adsorbent, the pore structure determines the gel adsorption capacity. Pores are characterized by specific surface area, specific pore volume (total volume of pores peg gram of solid), average pore diameter, pore size distribution and the degree to which entrance to larger pores is restricted by small pores. These parameters are derived from gas or vapor adsorption isotherms, mercury penetration studies, low angle X-ray scattering, electron microscopy, and gas permeability or measurement of the volume of imbibed liquid.
MSE #1840 4 - 2~ ~'~~ ~~
The most common way of preparing silica gel involves acidification of sodium silicate to a pH less than about 10. Silica can be gelled in spherical form by spray-drying, or by spraying droplets onto an immiscible liquid.
Precipitated silica (also called particulate silica) is composed of aggregates of ultimate particles of colloidal size that have not become linked in a massive gel network. Precipitated silicas are either formed from the vapor phase (fumed or pyrogenic silicas) or by precipitation from solution. In the preparation of pyrogenic or fumed silica, sand is vaporized at about 2000°C. On cooling, anhydrous amorphous silica powders form in thb presence of a reducing agent such as coke. The amorphous silica sublimes at about 1500°C
to provide Si which is then oxidized to produce par-ticulate Si02. Pyrogenic or fL~med silica is typically used as a thixotropic agent in polyester-glass rein°
forced plastics; as a reducing and thickening agent in 0 rubber, plastics, silicone and epoxy resins as well as a thickening and helping agent.
Pure silica is composed of the elements silicon and oxyg~n~ Materials are still referred to as "silicas" after metals; metal oxides or metal salts are added; e.g. flint is a silica with added iron oxide.
Glass hay a defined composition between (K,Na)2~.
(Ca,Pb), 6S3.Oa and 5(K;Na)a0, 7(Ca,Pb)O alld 36~'ai0a with a general formula Of (K,Na)O-Si;,~~n_,,(CaPb)O-~S3n02n_,,-0(K,Na). While asl s~.lica based glasses can be'called silicas, not alb. silicas are glass. The HDL adsox~bant MSE #1840 ;.

materials useful in the present invention are porous silica or silicates as these terms are used in their broadest sense.
Microporous silica gels are obtained by heating a hydrated gel at 1000°C for about IO hours. Siliceous materials can be made with extremely small pores such as is the case with impervious silica, porous glass and silica used as an adsorbent for certain specific materials. The ability of a material to be adsorbed is determined by the surface composition and pore size of the silica gel. The present invention is concerned with the use of large pore silicas and silicates such as microporous silica, silica gel and controlled pore glass as selective adsorbent materials for HDL from blood serum or plasma.
United States patent 5,141,872 discloses the use of fumed silica for the adsorption of lipoproteins from plasma. The patentees point out that this procedure was known before their invention but claim the im-Provement of selectively desorbing HDL from the fumed silica by incubating with a detergent containing formulation. Commercially available fumed silicas such as CAB-O-SILTM from Cabot Company and AerosolTM from Degussa are mentioned as being useful in this procedure.
The diameters of the LDL and VLDL particles are estimated at 220-250 ~ and 300-800 A respectively with chylomicrons being somewhat larger. Since the dimen-sions of a fumed silica such as AerosolTM 380 are less than about 70 ~ and the HDL particle is estimated at MSE #1840 -100 to 150 A in diameter, it can be concluded that this binding of lipoproteins as disclosed in U.B. 5,141,872 is based solely on non-specific surface adsorption.
Particle size exclusion of the relatively larger lipoprotein particles is not a factor in that method since LDL and VLDL particles are too large to fit in any pores which may exist in the 70 ~ particles. This prior art technique achieves its selectivity by desorption in a separate step, whereas the present invention involves the selective adsorption of the smaller HDL particles by the silica gel which, when combined with a mechanism for the separation of 'SILDL
and chylomicrons, provides a fluid sample which can be analyzed for the remaining LDL without further treatment.
Summary of th~ Inv~ntion The present invention involves a dry phase device for separating high density lipoprotein from a blood sample. The device comprises a first layer of fluid permeable material having dispersed therein finely divided, porous silica or silicate particles as adsor-bent for the HDL. The particles are characterized by having a size of from 1 to 1000 a in their longest dimension and surface pores of from abaut 80 A to 1000 R in size. The section of silica or silicate containing material can be combined with a second layer of a fluid permeable material bearing reagents for selectively removing very low density lipoprote~.ns and chylomicrons from the blood sample and filtering the complex formed therein i:hrough a sub-micron filter to leave low density lipoprotein as the only lipoprotein in the M8E #1840 - ' - ~~.~.7~.~_ blood sample. When these layers are combined with a third layer comprising a porous matrix containing a reagent system for the quantitative analysis of lipo-protein, there is provided a unitary device for the one step determination of low density lipoprotein.
In an alternative embodiment, the reagents of the first and second layers can be combined into a single layer.
Also included within the scope of the present invention is a method for the one-step determination of low density lipoprotein which involves applying a blood sample to the upper surface of the device described above.
D~scri.~tion ~f th~ Tnv~ntign ~h~ present invention has application in medical diagnostics in situations where it is desirable 'to remove the HDL component from a mixture of lipoproteins in plasma or serum. Examples of such a technique include using the system as a component of a system where other lipoproteins are also removed to thereby leave only a single lipoprotein which can be directly measuxed by a cholesterol content assay. Combination ~f this system with mehns for removing chylomicrons and very low density lipoprotein (VLDL) results in a direct assay for low density ligoprotein (LDL) which is the li~'oprotnin of greatest interest.
Alternatively, subtraction of the value for cholesterol in a blood sample, treated as suggested NLSE #1840 herein, from the value of total cholesterol in the original sample would allow one to deduce the amount of cholesterol carried by HDL in the sample.
In another application, 'the invention can be used as a means of dispensing lipoprotein interactive reagents in small, precise quantities, particularly where the silica reagent would be used in a subsequent procedure requiring the removal of particular lipopro-teins from serum or plasma. ~'or ease of the manufacture of medical diagnostic devices, the lipoprotein inter-active reagents could be evenly distributed in a dry sheet. By cutting out a well defined area of the sheet an accurate quantity of the active reagents would be at hand for convenient transfer to the desired container or location.
In its simglest form, the present invention is a layer of fluid permeable material capable of transmit-ting low- and very low-density lipoproteins but which blocks the transmission of high density lipoprotein in the fluid being tested.
The use of the particulate/porous silica gel immersed in a fluid permeable matrix as disclosed herein is believed to result from a surface interaction with the silica ~s well as by size exclusion. The HDL
component is removable by size exclusion and adsorption, i.e. the HDL is interactive with silica gel h'aving'a mean pore diameter greater than the diameter of an HDL
particle, and is most useful when the silica pare size is small enough to diminish the interaction of the MSE #1840 s.
_ g _ larger lipoprotein particles such as LDL and VLDL
therewith. Silicas of particle size from about 1 to 1000 a (preferably 3 to 10 u) in their longest dimension and having a range of pore sizes of from 80 A to 1000 A
(preferably 300 A to 500 A) have shown the best selec-tivity and efficiency for HDL particle removal. A good example of such silica is VYDACTM 101 TP from The Sepa-rations Group, Hesperia, CA. Other examples of effective silicas in their order of decreasing effectiveness are as follows:
1) Crosfield SorbisilTM C500 40/60;
2) Regis Chemical Co. 023001; 300 A/3 a silica 3) E.M. Merck LichosphereTM Si 300; 300 A pore silica 4) E.M. Merck FractosilTM 500; 420-490 A pore silica 5) E.M. Merck FractosilTM 200; 200 A pore silica 6) E.M. Merck FractosilTM 1000; 1000 A pore silica 7) E.M. Merck LichrosorbT"' Si 100; 100 A pore silica 8) Whatman PartisilTM 5; 5 ~t/66-88 A pore silica 9) Regis Chemical Co. 024000; 100 A pore silica In practicing the invention, the silica gel is entrapped in a porous layer by formation of a fibrous network around the particles, as in the case of papers and felts, or by adhesively joining the silica to other fibers or particles which are incorporated easily into the matrix, e.g. by coating a fiber with an adhesive such as cement by running it through a bath of the adhesive followed by contact with the silica particles, MSE #1840 curing the cement and washing off loosely bound parti-cles. The fiber strand would then be fragmented for use in a felt or woven into a fabric. Entrapment of the silica gel involving fibers may be assisted by a binder, such as starch or polyvinyl alcohol, to increase the du:-ability of the silica containing layer. Glass is the preferred fiber. Other man made fibers such as plastics containing hydrophilic groups or natural fibers such as cellulase, wool or silk can be used.
Ideally, the silica containing layer is combined with a separate fluid permeable layer of a matrix having dispersed therein reagents for the selective retention of VLDL and chylomicrons to provide'a fluid sample containing only LDL. Suitable agents for this part of the present system include a divalent ration and a polyvalent anion. The divalent ration is typically in the form of MnCI~ or MgCla, and the poly-valent anion is typically heparin or dextran sulfate.
A combination of heparin/MnCl,; is preferred. While the serum or plasma sample being tested may be pretreated to remove VLDL and chylomicrons, a preferred technique involves dispersing t:he divalE=nt ration/ polyvalent anioa~ cornbinat~.on a.n a porous matrix material such as glass fiber, cellulose or a felt or fabric of natural or man made fibers to provide a dry phase system for the VLDL/chylomicron removal step. The dry matrix material can be readily prepared by dipping the dry matrix substrate in an aqueous so~.ution of the divalent cation/polyvalent anion. 3t has been discovered that Preparation of the matrix base by contacting it with an aqueous system having a polyanion concentration of MSE #1840 0.15 gm/liter of the polyanion and a divalent cation concentration of ? 350 mM provides the best separation of VLDL and chylomicrons from the blood sample being treated.
This invention is a dry phase assay and can be used to assay for LDL with only small quantities of blood thus allowing the feasibility of a one-drop assay for direct LDL cholesterol measurement. Typically plasma or serum is used although whole blood is suitable when the device is provided with a layer of material capable of filtering erythrocytes. This system provides a complete assay with a single measurement in which the response is derived from an intimate interaction of the analyte of interest.
The method of practicing the present invention is further illustrated by the following examples.
EXAMPLE I
A saturated solution of cornstarch (8.2 mg corn-starch in 2.05 ml water) was prepared by heating to near boiling after which the solution was allowed to cool to room temperature and the insoluble portion was discarded. A 1.12 mL portion of the solution was mixed with 112 mg of long fiber cellulose (Sigma Chemical Co.) and 57 mg of microporous silica (VYDACTM 101 TP from The Separations Group). The slurry was cast onto a 1.9 cm diameter suction filter with a nylon mesh mat (CMM
10) in place as a bed for the slurry. When dry, the nylon mat with the fibrous circle was removed from the MSE #1840 funnel and the fibrous disk was calendered by overlaying a nylon mesh and applying pressure. The resulting paper like disk was sliced into 0.2 x 0.2 inch squares and placed over a 0.2 x 0.2 inch square with openings above and below the stack of layers. Human plasma was applied to the top of the opening and the effluewt plasma was collected from the bottom opening by holding a small glass capillary.against the membrane. The effluent was analyzed by agarose (Beckman Lipogel) gel _.e>
electrophoresis (Beckman paragon system), lipid staining and optical densitometry (Beckman Appraise). Comparison of effluent plasma and the original, untreated plasma showed preferential removal of high density lipoproprotein (HDL) rather than low density lipoprotein (LDL) or very low density lipoprotein ('VLDL). These data are set out in Table 1.

Ratio Stip (Effluent/
Lipoprotein Original Effluent Original) HDL 2 "7 . 8 10 . 0 0 . 3 6 VLDL 6.9 7:7 1,11 LDL 33.8 34.1 1.01 EXAMPLE TI
A dry reagent strip or ~,rell type; device for determining LDL in whble blood samples was fi'tted~with a stack of materials as described below. Referring to the drawing, the Mack consists of three layers for LDL
selection; a glass felt containing porous silica for MSE #1840 filtering red blood cells and capturing HDL (1), a glass fiber layer containing heparin and a manganese salt (MnCl2) (3) and a submicron filter layer (5).
Beneath these layers is a cholesterol indicating membrane (7) containing reagents for the breakup of lipoprotein particles, the conversion of cholesterol esters to cholesterol and an ultimate color reaction dependent upon cholesterol concentration. The layers are prepared as follows:
Silica-Glass Felts:
In one method, glass wool, .33 g, was ground to small fiber segments in 1% aqueous polyvinyl alcohol with a mortar and pestle. The resulting slurry was stirred and poured into a Buchner funnel (sans vacuum) with a tight mesh nylon or commercial glass fiber (Whatman GF/A) layer over the frit and the layer was allowed to settle to a mat. A mixture/slurry of 0.57 g silica (VYDACTM 101 TP) (calculated to give 20 mg/cm2 for the final circle area) and .33 g glass fiber segments was then poured onto a 20 ml layer of 1% polyvinyl alcohol fluid over the first fiber and allowed to settle. More glass wool, .33 g, was ground to small fiber segments in 1% aqueous polyvinyl alcohol with a mortar and pestle. The slurry was stirred and poured onto a 20 ml layer of 1% polyvinyl alcohol fluid over the silica/glass fiber mat and allowed to settle.
Vacuum was then applied to draw the fluid and partially dry the mat. The felt mat was then removed along with the support layer and dried in a 50 degree C forced air oven .
MSE #1840 i By another method, a slurry of VYDACTM silica 101/TP
(at 20 mg/cm2 for the final layer), 1% aqueous corn starch and ground Pyrex glass wool (at 35 mg/cm2) was cast onto a pool of 1% aqueous corn starch over com-mercial glass fiber filter, e.g. Whatman G/F A. The agitated slurry was suctioned down into an even layer and the composite layer was dried in a 50 degree C. air dryer.
The next layer consisted of a glass fiber filter of Whatman PD107 which has been impregnated with heparin and manganese. The impregnation Was accomplished by submerging the glass fiber sheet in a solution con-taining 0.15 mg/ml heparin and 350 mM manganese chlo-ride. The sheet was then wiped free of excess surface clinging solution and dried by heated air. This treated glass fiber material was then layered over a porous filtering layer (0.2 micron pore Loprodyne from Pall Ultrafine Filtration Co.). These layers were then placed on top of a reductive indicator membrane con-taining reagents for the de-esterification of choles-terol esters and break up of lipoprotein with the ultimate color reaction being derived from cholesterol.
The stack was held firmly in place in a well type device, i.e. a stack of molded plastic parts welded together. This device allows blood to enter at the top of the stack which is positioned over a clear window so that color change can be measured in a small reflectance photometer. This color change is correlated to the lipoprotein remaining in the blood sample when it reaches the detection layer.
MSE #1840 EXAMPLE III
Serum was added to a slurry of MnCl2, porcine heparin in the ratio of 2 parts serum to 1 part MnCL2-heparin solution to 111.1 mg silica VYDACTM 101TPB4/ml serum. The treated serum sample was mixed by vortexing and allowed to stand at room temperature for approxi-mately 12 minutes before centrifuging at 12,000 X g for 3 minutes. The total cholesterol of the infranate was determined on a Roche Cobas Fara Clinical analyzer.
The LDL-cholesterol values were obtained by multiplying the infranate total cholesterol by 1.5. Friedewald LDL-cholesterol values were calculated from independent determinations of total cholesterol, HDL-cholesterol and triglycerides according to the formula:
LDL Chol. - Total Chol. -HDL Chol.- Triqlycerides Values obtained using the method of the present invention (direct LDL cholesterol) are compared with those values determined by the Friedewald method. The correlation coefficient between the present method and the Friedewald method was 0.98 as can be determined from Table I.
MSE #1840 i TABLE I
Direct LDL Friedewald LDL
Sample Cholesterol Cholesterol Number (mg/dl~ (mg/dL) -EXAMPLE IV
Selective Removal of HDL From Serum by Microporous Silica To 1.5 mL plastic microcentrifuge vials containing (1) microporous silica fvYDACTM 101TP; 270 - 320 ~1 average 300 R pore size from The Separations Group, Hesperia, CA], (2) controlled pore glass [330 A pore, PG 350-200, Sigma Chemical Co.], (3) controlled pore glass [79 ~I pore, PG 75-200] or (4) amorphous fumed silica (non-porous CAB-O-SILTM, Grade M5, 2 ~t aggregates, Cabot Corp.) was added approximately 300 uI. of fresh human serum. A fifth vial containing no silica was used as a control. The contents of the vials are summarized in Table 2.
MSE #1840 I

_ 17 _ f f r1 i o O ,n n a, .1 O
,p~ m V

..U
a N

'O

N

a~

w~

o .~ e vo .-~ o, ro a a o f wo v °O,..VW .~ ~ci ~o o .i 'b .i c~ r.
U t!~ ~ ~
cr Ga O
EI m n1 .-~ ~ r~
i .-i rf o m c .-i Oo ~H
ai i C u~ ..~ o m O n .~ en n U .-~ f V
O O O
O
M
U
'd E
.., a .i Sa a o d E tn m E E
MSE #1840 Each tube was capped, briefly vortexed, placed in a larger cylindrical tube and simultaneously placed on a rolling hematology mixer (Fisher Scientific) for 15 minutes. The vials were then centrifuged for 8 minutes at 14,000 X g. Approximately 225 uL of clear super-natant fluid was transferred from each vial to a new vial, capped and vortex mixed. The treated samples and the original human serum were analyzed by agarose gel (Beckman Lipogel) electrophoresis (Beckman Paragon System), lipid staining and optical densitometry (Beckman Appraise). Comparison of treated serum results to untreated serum indicated preferential removal of HDL over that of LDL or VLDL by the micro-porous silicas (VYDACTM) and the 330 A controlled pore glass. There was observed no useful selectivity for HDL by the fumed silica or PG 75-200 controlled pore glass. In this experiment, absorbance units were obtained using the Beckman Appraise Densitometer for each 0.1 mm of the scan of each electrophoresis gel lane. Absorbance at 600 nm was normalized to that of the Hewlett Packard 8452A Spectrophotometer by dividing the raw appraise absorbance data by a factor of 2200.
This factor was arrived at by comparison of the response to a blue transparent film standard on each instrument.
The absorbance values were converted to % recovery of lipoproteins by the formula 100% X [absorbance X width (nm) of the experimental lipoprotein band]/[absorbance X width (nm) of the control lipoprotein band]. The results of this experiment, both in terms of absorbance and % recovery of lipoproteins are set out in Tables 3 and 4:
MSE #1840 ~o E

ro U
~
u1 ..~
_~
u1 NO

~
E

d ~U
vo m wo t.. o n N o E

.a o O O "' .a N

.d N

C7 07 O ~- ~ ~
ro r~ ao N U O
.-i ~ , ~

~ O .~ ~
m U1 t O~a~ U

H GW

O H
~

~

U
~

M ad w wwx od O CJ
N
O

,~ ~.
N U room o o N r-~p ro m d ,.., o 0 0 ~7 in ,s ~M

'' w ro w .n , "' .
n C .4 ~o d ra H ~'i N

ro 4~ .a O 01 O C~
d U N O M M

1J iJ ..~
W ri O

~

O ~4 U

p a~

CL
r -~ u~ r M M

O N N ~O

y,i O
O

C

O

U

N

~ O

..
i d H

.N U

a E

' a ' o a A

.e a v x ~ a MSE #1840 a E

m O, i a~.-~r~

E i N

i U In .r ..i~

~

O

W S7 m a d rt 1 uwo o, E

E U~ 1 O <T i t>4 E

'O

C

to m CA O f r-~ 0 m O 1 U l N 01 N
., .1 i U

,.1 O ~ I .~N
U7 .i d a b 1 .~ ., a~ ~, om y1 O ?~
H ~
C

O it ~
O UJ
.i N U
.C

f~ GL ~-1 a~

O O ~
O

G1 .l f H

.a y ago .r d w ...1 ., w m owa H ~ m N
~

H ~ Np l n a' o i , .l~

..,>

~ 1 .-..~ o o ~ ~ U
m ~

...1 d U" i.1 W M
O

~

CI
d ~tx w p d E .p eP

.-1 G! -- l7 O

~o H

~ i w .. o o a -a .1 s r a.1 H N 1 0,ao c d o Q, lJ 1 1 C N .~ 1.1 W

1 ~'.~ .r O n O
~C

U

U' "a v1 o.
n O

O

O

O

d a >

a~ H

U .-1 O p A U

r o-a U x > a m MSE #1840 For controlled pore glass used at 111 mg/mL, the calculated recovery of HDL and LDL was 109% and 110%
respectively for the 80 R pore material and 7% and 100%
respectively for the 300 A pore material. The micro-s porous silica, VYDACTM lOlTP, recovered HDL/LDL at 12%/112% when used at 111 mg/mL. Previous experience with fumed silica suggested that lipoprotein removal by 111 mg/mL silica is so complete that no information on selectivity can be gained by electrophoresis of the treated serum. Accordingly, more appropriate amounts of CAB-O-SILTM were used. At 5 mg/mL the percent recovery of HDL/LDL was 3%/4% respectively. At a lower level (11 mg CAB-O-SILTM/mL serum) the percent recovery HDL/LDL was 59%/65% respectively. Accordingly, it can be seen that while fumed silica removes HDL from serum, it exhibits no useful preference for abstraction of HDL
over LDL. The quantity of chylomicron lipoprotein in the original sample was too small to allow a reliable percent recovery number to be calculated.
MSE #1840

Claims (10)

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:
1. A device for separating high density lipoprotein, very low density lipoprotein and chylomicrons from a blood sample containing high density lipoprotein, low density lipoprotein, very low density lipoprotein and chylomicrons which device comprises a layer of fluid permeable material which has dispersed therein finely divided, porous silica gel particles having a particle size of from 1 µ to 1000 µ
in their longest dimension and surface pores of from about 80 .ANG. to 1000 .ANG. in diameter, which silica gel particles demonstrate a selective affinity for high density lipoprotein as compared to low density lipoprotein, very low density lipoprotein and chylomicrons and wherein there is dispersed in the layer of fluid permeable material, or in fluid communication with the layer, a reagent system having affinity for very low density lipoproteins and chylomicrons to form a complex with the very low density lipoproteins and the chylomicrons together with means to separate said complex from the blood sample thereby leaving a blood sample substantially free of all lipoprotein but low density lipoprotein.
2. The device of Claim 1 wherein the silica gel particles are from 3 µ to 10 µ in their longest dimension and the pores have a diameter of from 300 .ANG. to 500 .ANG..
3. The device of Claim 1 wherein the reagent system comprises a polyanion and a divalent cation.
4. The device of Claim 3 wherein the reagent system is applied to the fluid permeable material by contacting the fluid permeable material with an aqueous system having dissolved therein a polyanion at a concentration of no greater than 0.15 gm/liter and a polyvalent cation at a concentration equal to or greater than 350 mM.
5. The device of Claim 3 wherein the polyanion is heparin and the cation is Mn++.
6. The device of Claim 3 wherein the polyanion is dextran and the cation is Mg++.
7. The device of Claim 1 wherein the reagent system is included in a second layer of fluid permeable material located beneath the layer of fluid permeable material having said silica particles dispersed therein and in fluid communication therewith and the means to separate the complex from the blood sample is a submicron filter located beneath said second layer and in fluid communication therewith to filter the very low density lipoprotein-chylomicron/reagent complex to provide a blood sample substantially free of all lipoprotein but low density lipoprotein.
8. The device of Claim 7 wherein there is a layer adjacent to and in fluid communication with the submicron filter, which contains a reagent system for the detection of total cholesterol contributed by the low density lipoprotein in the blood sample.
9. A method for the separation of high density lipoprotein from a blood sample which comprises placing the blood sample on the surface of the device of any one of Claims 1-8 to thereby allow the sample to permeate the fluid permeable material which retains the high density lipoprotein to thereby provide a blood sample essentially devoid of high density lipoprotein.
10. The method of Claim 9 wherein the fluid permeable material comprises glass fiber, a polymeric fiber containing hydrophilic groups or a natural fiber.
CA002117118A 1993-06-01 1994-03-07 Device for the direct measurement of low density lipoprotein cholesterol Expired - Fee Related CA2117118C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/069,420 US5401466A (en) 1993-06-01 1993-06-01 Device for the direct measurement of low density lipoprotein cholesterol
US08/069,420 1993-06-01

Publications (2)

Publication Number Publication Date
CA2117118A1 CA2117118A1 (en) 1994-12-02
CA2117118C true CA2117118C (en) 2003-01-14

Family

ID=22088859

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002117118A Expired - Fee Related CA2117118C (en) 1993-06-01 1994-03-07 Device for the direct measurement of low density lipoprotein cholesterol

Country Status (5)

Country Link
US (1) US5401466A (en)
EP (1) EP0627627A1 (en)
JP (1) JP3425801B2 (en)
AU (1) AU676285B2 (en)
CA (1) CA2117118C (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3929032C2 (en) * 1989-09-01 1998-09-03 Boehringer Mannheim Gmbh Method for the determination of HDL cholesterol by means of a rapid diagnostic with integrated fractionation step
USRE39915E1 (en) 1989-09-01 2007-11-06 Roche Diagnostics Gmbh Method for the determination of HDL cholesterol by means of a rapid diagnostic agent with an integrated fractionating step
WO1996015453A1 (en) * 1994-11-14 1996-05-23 Spectral Diagnostics Inc. Method and device for determination of proteins employing antigen/antibody reactions
AUPN030794A0 (en) 1994-12-22 1995-01-27 Aruba International Pty Ltd Discontinuous plasma or serum delipidation
JP3193634B2 (en) * 1996-05-29 2001-07-30 第一化学薬品株式会社 LDL cholesterol determination method
US5945345A (en) * 1996-08-27 1999-08-31 Metrika, Inc. Device for preventing assay interference using silver or lead to remove the interferant
TW457284B (en) * 1997-09-12 2001-10-01 Cytec Tech Corp Water based primer compositions and their use for treating metal surfaces
US20060019404A1 (en) * 1998-05-06 2006-01-26 Blatt Joel M Quantitative assay with extended dynamic range
JP3441993B2 (en) * 1999-01-27 2003-09-02 松下電器産業株式会社 Cholesterol sensor
EP1227888A4 (en) * 1999-09-13 2006-05-24 Millipore Corp High density cast-in-place sample preparation card
US6869572B1 (en) * 1999-09-13 2005-03-22 Millipore Corporation High density cast-in-place sample preparation card
DE60018039T2 (en) 1999-11-22 2005-09-29 Matsushita Electric Industrial Co., Ltd., Kadoma SENSOR AND METHOD FOR MEASURING CHOLESTEROL
US7407662B2 (en) 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
US7439052B2 (en) * 2000-06-29 2008-10-21 Lipid Sciences Method of making modified immunodeficiency virus particles
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
US7407663B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
US20090017069A1 (en) * 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
EP1412045A4 (en) * 2001-06-25 2007-05-02 Lipid Sciences Inc Systems and methods using a solvent for the removal of lipids from fluids
US20030127386A1 (en) * 2001-06-25 2003-07-10 Bomberger David C. Hollow fiber contactor systems for removal of lipids from fluids
AU2002322284A1 (en) * 2001-06-25 2003-01-08 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
US6991727B2 (en) * 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
US20060060520A1 (en) * 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
US6844149B2 (en) 2001-06-29 2005-01-18 International Business Machines Corporation Method, system, and apparatus for measurement and recording of blood chemistry and other physiological measurements
DE10204606C1 (en) * 2002-01-18 2003-10-16 Cholestech Corp Device and method for high density lipoproteins
DE60207196T2 (en) * 2002-04-09 2006-07-20 Cholestech Corp., Hayward Method and apparatus for quantification of high density lipoprotein cholesterol
US20040050787A1 (en) * 2002-09-13 2004-03-18 Elena Chernokalskaya Apparatus and method for sample preparation and direct spotting eluants onto a MALDI-TOF target
US6928657B2 (en) 2002-10-25 2005-08-16 Kimberly-Clark Worldwide, Inc. Face mask having hook and loop type fastener
CN100374695C (en) * 2002-10-31 2008-03-12 保氏直线发展有限公司 Combustion engine
US7032751B2 (en) * 2002-12-19 2006-04-25 Kimberly-Clark Worldwide, Inc. Dispensing assembly for single piece face mask
EP1434054A1 (en) * 2002-12-25 2004-06-30 Matsushita Electric Industrial Co., Ltd. Biosensor for determining low density cholesterol
TWI333545B (en) * 2003-04-02 2010-11-21 Cholestech Corp Adhered membranes retaining porosity and biological activity
US7393826B2 (en) * 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
ES2547547T3 (en) * 2003-07-03 2015-10-07 Hdl Therapeutics, Inc. Enrichment of pre-beta high density lipoproteins
US6960803B2 (en) * 2003-10-23 2005-11-01 Silicon Storage Technology, Inc. Landing pad for use as a contact to a conductive spacer
US20050092504A1 (en) * 2003-11-03 2005-05-05 Walthall Lacy M. Personal electromagnetic security unit and method for electromagnetically shielding portable electronic communication and data devices and the like
US20050124019A1 (en) * 2003-11-04 2005-06-09 Jones Ronald M. Reagent-containing membranes and laminates and methods of their preparation
US7150995B2 (en) * 2004-01-16 2006-12-19 Metrika, Inc. Methods and systems for point of care bodily fluid analysis
US7435577B2 (en) * 2004-02-03 2008-10-14 Polymer Technology Systems, Inc. Direct measurement of chlolesterol from low density lipoprotein with test strip
US20050227370A1 (en) * 2004-03-08 2005-10-13 Ramel Urs A Body fluid analyte meter & cartridge system for performing combined general chemical and specific binding assays
US7772007B2 (en) * 2004-04-02 2010-08-10 Cholestech Corporation Assay device for direct measurement of LDL cholesterol
CN2698358Y (en) * 2004-04-06 2005-05-11 上海江夏血液技术有限公司 Blood filtering device
US7491542B2 (en) * 2004-07-12 2009-02-17 Kim Scheuringer Test device for determining the concentration of LDL-cholesterol in a sample
US8622059B2 (en) 2004-12-21 2014-01-07 Kimberly-Clark Worldwide, Inc. Face mask with absorbent element
US20060130841A1 (en) * 2004-12-22 2006-06-22 Kimberly-Clark Worldwide, Inc Face mask with horizontal and vertical folds
US7725948B2 (en) * 2004-12-22 2010-06-01 Kimberly-Clark Woldwide, Inc. Face mask with offset folding for improved fluid resistance
US7290545B2 (en) * 2004-12-23 2007-11-06 Kimberly-Clark Worldwide, Inc. Face mask with anti-fog folding
US20100224199A1 (en) * 2006-05-01 2010-09-09 Kimberly-Clark Worldwide, Inc. Respirator
WO2008086019A1 (en) * 2007-01-09 2008-07-17 Cholestech Corporation Device and method for measuring ldl-associated cholesterol
US8247235B2 (en) 2007-06-08 2012-08-21 Quest Diagnostics Investments Incorporated Lipoprotein analysis by differential charged-particle mobility
EP2645102A3 (en) * 2007-06-08 2014-01-22 Quest Diagnostics Investments Incorporated Lipoprotein analysis by differential charged-particle mobility
US20090044811A1 (en) * 2007-08-16 2009-02-19 Kimberly-Clark Worldwide, Inc. Vent and strap fastening system for a disposable respirator providing improved donning
US9642403B2 (en) * 2007-08-16 2017-05-09 Kimberly-Clark Worldwide, Inc. Strap fastening system for a disposable respirator providing improved donning
US9354200B1 (en) 2008-08-07 2016-05-31 Quest Diagnostics Investments Incorporated Detection apparatus for differential-charged particle mobility analyzer
US9250211B2 (en) 2010-12-30 2016-02-02 Quest Diagnostics Investments Incorporated Magnetic separation of lipoproteins using dextran sulfate
JP5355674B2 (en) * 2011-01-11 2013-11-27 富士フイルム株式会社 Method for removing high density lipoprotein in blood
WO2014072363A1 (en) * 2012-11-06 2014-05-15 Nanologica Ab A porous silica material for use as a pharmaceutical or dietary active ingredient
USD746439S1 (en) 2013-12-30 2015-12-29 Kimberly-Clark Worldwide, Inc. Combination valve and buckle set for disposable respirators
CA3083194A1 (en) 2017-11-22 2019-05-31 Hdl Therapeutics, Inc. Systems and methods for priming fluid circuits of a plasma processing system
EP3731814A4 (en) 2017-12-28 2021-09-29 HDL Therapeutics, Inc. Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma
CN109799528B (en) * 2019-01-17 2022-08-19 中国辐射防护研究院 Oxidized gel for sampling radioactive contaminated metal shallow layer and preparation method thereof
CN113710344A (en) 2019-05-01 2021-11-26 奥升德功能材料运营有限公司 Filter media comprising a polyamide nanofiber layer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4167467A (en) * 1977-09-21 1979-09-11 Helena Laboratories Corporation Clinical procedure for measuring lipoprotein free cholesterols
US4185963A (en) * 1977-10-03 1980-01-29 Conoco Inc Method for determining lipids in blood serum
US4234317A (en) * 1979-05-24 1980-11-18 Analytical Products, Inc. Apparatus and method for fractionation of lipoproteins
US4290774A (en) * 1980-01-07 1981-09-22 Miles Laboratories, Inc. Purification of lipoprotein cholesterol for use as a cholesterol reference material
DE3007764A1 (en) * 1980-02-29 1981-10-15 Boehringer Mannheim Gmbh METHOD AND REAGENT FOR DETERMINING THE BETA LIPOPROTEINS
JPS5810056A (en) * 1981-07-10 1983-01-20 株式会社クラレ Blood purifying apparatus
DE3280188D1 (en) * 1981-09-10 1990-07-19 Braun Melsungen Ag DEVICE FOR SELECTIVE EXTRACORPORAL PRECIPATION OF LOW DENSITY LIPOPROTENS FROM FULL SERUM OR PLASMA.
US4845198A (en) * 1984-05-21 1989-07-04 Immunex Corporation Hybridoma antibody which binds IL-2 receptor
CA1279593C (en) * 1985-05-10 1991-01-29 Makram Melek Girgis Cholesterol-rich fraction, process therefor and use thereof in cell culture
IL79945A (en) * 1986-09-04 1991-06-10 I D L International Diagnostic Method for the quantitative determination of total cholesterol in blood
US5215886A (en) * 1987-06-22 1993-06-01 Patel P Jivan HDL determination in whole blood
US4968432A (en) * 1988-05-18 1990-11-06 Cobe Laboratories, Inc. Treatment of liquid including blood components
IL89123A (en) * 1989-01-31 1993-08-18 Ilana Tamir Method for determination of ldl-cholesterol
US5135716A (en) * 1989-07-12 1992-08-04 Kingston Diagnostics, L.P. Direct measurement of HDL cholesterol via dry chemistry strips
US5118613A (en) * 1989-11-17 1992-06-02 Abbott Laboratories Determination of hdl whole blood
US5168067A (en) * 1990-05-25 1992-12-01 Miller Michael A Method and kit for screening for apolipoprotein b or calculated ldl cholesterol
US5213965A (en) * 1990-07-16 1993-05-25 Cholestech Corporation Solid-phase precipitation assay device
US5242833A (en) * 1991-03-20 1993-09-07 Reference Diagnostics, Inc. Lipid fractionation
US5078853A (en) * 1991-03-22 1992-01-07 Assay Technology, Inc. Segmented electrophoretic separation system useful for lipid profiling
US5286626A (en) * 1991-12-13 1994-02-15 Actimed Laboratories, Inc. Process and apparatus for direct determination of low density lipoprotein
US5290703A (en) * 1992-12-14 1994-03-01 Miles, Inc. Method for the separation of high density lipoprotein from blood samples

Also Published As

Publication number Publication date
CA2117118A1 (en) 1994-12-02
US5401466A (en) 1995-03-28
JPH0755812A (en) 1995-03-03
AU6311694A (en) 1994-12-08
EP0627627A1 (en) 1994-12-07
JP3425801B2 (en) 2003-07-14
AU676285B2 (en) 1997-03-06

Similar Documents

Publication Publication Date Title
CA2117118C (en) Device for the direct measurement of low density lipoprotein cholesterol
EP0602455B1 (en) Method for the separation of high density lipoprotein from blood samples
EP0767701B1 (en) Composite articles for separating mercury from fluids
US5316916A (en) High-density lipoprotein solid-base assay device
CN101784893A (en) Monolith adsorbent and method and apparatus for adsorbing samples with the same
JP2002512083A (en) Fiber member having odor adsorption ability and method for producing the same
JP2001506742A (en) Multilayer enzyme electrode membrane and method for producing the same
JP2001508701A (en) Silica adsorbent on magnetic substrates
CN107638868B (en) A kind of porous carbon adsorbent and its preparation method and application
JPS58146415A (en) Fibrous medium containing milimicron particle
JP3035359B2 (en) Refined natural glass products
Jiang et al. Ordered mesoporous silica film as a novel fiber coating for solid-phase microextraction
CN110314639B (en) Modified birnessite and preparation method and application thereof
GB2293481A (en) Iodine adsorption agent
CA1285721C (en) Device composed of polymers with a membrane structure and incorporated solids particles
Tomaić et al. Humic material polydispersity in adsorption at hydrous alumina/seawater interface
US4376828A (en) Bilirubin test kit
CN110314637A (en) A kind of modified goethite and its preparation method and application
JP6810583B2 (en) Enzyme sensor
Huo et al. Preparation and characteristic of triolein-embedded composite sorbents for water purification
US20180126356A1 (en) Chill-proofing composite filter air and related methods
CN116159549B (en) Hydrogen sulfide gas adsorption material and preparation method and application thereof
JP2589079B2 (en) Method for producing purified guaiac fat
CN112971205B (en) Application of graphene adsorption material in reducing harmful components in cigarette smoke
JPH0126504B2 (en)

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20040308